St. Louis, MO – August 5, 2015 GeneriCo, LLC, based in St. Louis, MO, announces that it has closed on $1.5M of an
anticipated $2.0M Series A funding round. GeneriCo is focused on developing and marketing niche generic
pharmaceuticals, particularly those having embedded drug delivery technology.
Kinsale Capital Partners, LLC is leading the Series A funding round. First closing investors include BioGenerator (the
early stage investment arm of BioSTL), Missouri Technology Corporation, accredited investors with industry
knowledge and Kinsale Capital’s own proprietary funds. The $2.0M Series A offering, which includes warrant
incentives, is expected to be fully funded and closed in Q4 2015. Kevin O’Shea, a Principal of Kinsale Capital Partners,
will join the GeneriCo Board as the representative of the Series A investors.
We are very excited and fortunate to partner with Kinsale Capital Partners and the other first closing investors, says
Tom Brya, GeneriCo’s President and CEO. We’ve made tremendous progress to date, and Kinsale’s leadership and
the extensive knowledge and strategic relationships of our first closing investors will enable us to expand our
operations aggressively over the next 18 months. We welcome Kevin to our Board.
GeneriCo’s management team brings over 150 years’ collective experience in the pharmaceutical industry along with
superior drug-formulation capabilities and the ability to exploit excess capacity at generic drug manufacturing
facilities. To this end, GeneriCo has already established a growing network of business partners. GeneriCo’s
strategic focus and innovative collaboration model makes us agile and reduces many of the risks inherent in the
generic drug development process, says Brya. GeneriCo expects to file three to four Abbreviated New Drug
Applications (ANDA) in 2016 with associated revenue projected to be realized in 2017.
Dan Broderick, VP of BioGenerator and Chairman of the Board of GeneriCo, expressed his satisfaction stating, This
represents an exciting new chapter in GeneriCo’s maturation as a company. BioGenerator is excited to support the
growth of GeneriCo in the traditionally strong pharmaceutical space in St. Louis. GeneriCo’s business plan, scientific
knowledge, and strong management team make this a particularly attractive investment.